Pictet Asset Management (Switzerland)’s Theravance Biopharma TBPH Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$19.1M	Buy	1,841,997 +387,730	+27%	+$4.28M	0.02%	480
2023 Q1	$15.8M	Buy	1,454,267 +961,879	+195%	+$10.2M	0.02%	520
2022 Q4	$5.53M	Buy	492,388 +122,009	+33%	+$1.28M	0.01%	722
2022 Q3	$3.76M	Buy	370,379 +108,952	+42%	+$1.02M	0.01%	798
2022 Q2	$2.37M	Buy	261,427 +74,643	+40%	+$688K	﹤0.01%	919
2022 Q1	$1.79M	Sell	186,784 -16,732	-8%	-$164K	﹤0.01%	979
2021 Q4	$2.25M	Hold	203,516	–	–	﹤0.01%	987
2021 Q3	$1.51M	Buy	+203,516	New	+$2.28M	﹤0.01%	1028

Other funds holding TBPH

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s TBPH Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Theravance Biopharma (TBPH) stake by 27% in Q2 2023, buying an estimated $4.28M and bringing the position to 1,841,997 shares worth $19.1M. The position accounts for 0.02% of the portfolio, ranked #480.

Pictet Asset Management (Switzerland) first reported a position in TBPH in Q3 2021 and has held it in 8 quarters since. 119 funds tracked by Wall St. Rank hold TBPH as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,841,997 shares of Theravance Biopharma worth $19.1M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 387,730 Theravance Biopharma shares in Q2 2023, an estimated $4.28M.
Theravance Biopharma made up 0.02% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #480 holding.
Pictet Asset Management (Switzerland) first reported a position in Theravance Biopharma in Q3 2021 and has held it in 8 quarters since.
119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.